four factor prothrombin complex concentrate
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Anticoagulation
Conditions
Anticoagulation, Anticoagulation Reversal
Trial Timeline
Mar 15, 2018 → Mar 31, 2022
NCT ID
NCT03473132About four factor prothrombin complex concentrate
four factor prothrombin complex concentrate is a approved stage product being developed by CSL for Anticoagulation. The current trial status is unknown. This product is registered under clinical trial identifier NCT03473132. Target conditions include Anticoagulation, Anticoagulation Reversal.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03473132 | Approved | UNKNOWN |
Competing Products
7 competing products in Anticoagulation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban | Pfizer | Approved | 84 |
| VKA + Apixaban + dabigatran + rivaroxaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Apixaban + Cofact (4-Factor PCC) + Beriplex P/N (4-Factor PCC) + Placebo (Saline solution) | Bristol Myers Squibb | Phase 1 | 32 |
| DOACs: Rivaroxaban, Dabigatran, Apixaban + Standard of care (Warfarin) | Bayer | Pre-clinical | 20 |
| Prismocitrate 18 | Baxter | Phase 3 | 74 |
| Prismocitrate 18 | Baxter | Phase 3 | 74 |